Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ConsumerLab on multivitamins

This article was originally published in The Tan Sheet

Executive Summary

Online testing group affirms 25 of 37 multivitamin products evaluated contain the labeled amount of ingredients, disintegrate properly for absorption and do not contain potentially harmful levels of lead, White Plains, N.Y.-based firm announces May 21. Thirteen of the 25 approved products were submitted by their manufacturers for testing under the firm's voluntary certification program. Brands okayed by ConsumerLab.com that were not submitted for testing are Twinlab, GNC,One-A-Day, Walgreens, Women's MultiStart, AARP Health Care Options, Enfamil supplement drops, Propel fitness water and Flintstones. Several failing products contained ingredients in smaller amounts than labeled and at least one product contained a "high amount" of lead, ConsumerLab says...

You may also be interested in...



ConsumerLab “Unfair,” “Deceptive” Practices Warrant FTC Action – CRN

The Council for Responsible Nutrition is asking FTC to take enforcement action against online testing service ConsumerLab.com to limit a number of allegedly deceptive practices central to the firm's business model

Supplement Content Test Method Validation At Issue In Gummy Vites Dispute

A public dispute between vitamin maker Northwest Natural Products and online testing firm ConsumerLab.com over test results highlights issues of test method validation and standard levels for contaminants in the dietary supplement industry

Roche/Genentech Keeps Commitment To External Cancer Innovation

Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.

Topics

UsernamePublicRestriction

Register

LL1135972

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel